ReviewMicroorganisms2026
Biosurfactants as Antibiofilm Agents for Medical Devices: Mechanisms, Evidence and Integration into Infection Prevention and Control.
Review in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lactobacillus strains in the prevention and disruption of antimicrobial-resistance in pathogenic microbial biofilms: a review of mechanisms and clinical perspective.Folia microbiologica · 2026Review
- Biosurfactants as Stabilizers of Silver Nanoparticles: A Sustainable Approach for Antimicrobial Applications.Microorganisms · 2026Article
- Biofilm Formation and Spore-Mediated Persistence of Clostridium perfringens in Meat and Poultry Processing Environments and Their Implications for Control Strategies.Journal of food science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilms rapidly form on medical devices such as urinary catheters and surgical materials. These biofilms compromise patient safety and undermine infection prevention and control (IPC). Biofilms also reduce the effectiveness of antibiotics and disinfectants. As a result, they increase healthcare-associated infections and increase costs through device failure and the need for maintenance or replacement. Researchers are increasingly exploring biosurfactants (BSs) as surface coatings and cleaning additives to prevent microbial attachment and disrupt early biofilm formation on medical devices and healthcare-related surfaces. This review examines the translational potential of biosurfactants as preventive, disruptive, and adjunctive antibiofilm agents for medical devices and healthcare-related surfaces. Literature evidence on glycolipids (rhamnolipids, sophorolipids) and lipopeptides (surfactin) from static, flow-based, and microfluidic in vitro models that used clinically relevant materials, such as silicone and polydimethylsiloxane (PDMS), were examined. In our literature search, we focused on pathogens central to IPC, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.